Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With Epilepsy
Launched by EISAI INC. · Apr 7, 2016
Trial Information
Current as of June 22, 2025
Completed
Keywords
ClinConnect Summary
This study is a retrospective study of participants who received perampanel as primary or secondary monotherapy at approximately 40 centers in Europe, Asia, and Australia. Primary monotherapy is defined as the administration of perampanel in the absence of any concomitant antiepileptic drugs (AEDs). Secondary (conversion) monotherapy is defined as the conversion of perampanel from adjunctive therapy to monotherapy by withdrawing concomitant AEDs.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of epilepsy
- • Received perampanel as primary or secondary monotherapy at any time between 1 Jan 2013 and 15 Oct 2015
- • Provided written informed consent by the participant or the participant's legally authorized representative signed for the use of medical records per local requirements
- Exclusion Criteria:
- • Not applicable
About Eisai Inc.
Eisai Inc. is a global pharmaceutical company committed to providing innovative solutions for patients with unmet medical needs. With a strong focus on neurology and oncology, Eisai leverages cutting-edge research and development to advance therapeutics that enhance patient outcomes and quality of life. The company emphasizes a patient-centric approach, fostering collaboration with healthcare professionals and stakeholders to ensure the effective delivery of its products. Eisai Inc. is dedicated to upholding the highest ethical standards in clinical trials, driving scientific excellence, and contributing to the advancement of healthcare worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Karen Cartwright, PhD
Study Director
Eisai Limited
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials